biotech · Alzheimer Disease · Friedreich Ataxia · LXEO
Lexeo Therapeutics
Lexeo Therapeutics is a biotech organization headquartered in New York, USA. It trades on NYSE under ticker LXEO. Primary therapeutic focus areas include Alzheimer Disease, Friedreich Ataxia, Arrhythmogenic Cardiomyopath
New York, USA HQ
2018 Founded
91 Employees
Public company Type
LXEO · NYSE Ticker
Company details
- Status
- Public
- HQ
- New York, USA
- Founded
- 2018
- Employees
- 91
- Programs
- 3
- Drugs
- 4
- Patents
- 0
LX1001
Phase 1 · mab · Alzheimer Disease
LX1001 for Alzheimer Disease is a Phase 1 program (mab) at Lexeo Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code LX1001-02
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Lexeo Therapeutics
- Phase
- Phase 1
- Modality
- mab
- Indication
- Alzheimer Disease
- Status
- active
- Trials
- 1